Mostrar el registro sencillo del ítem

dc.contributor.authorMacías, Juan
dc.contributor.authorMancebo, María
dc.contributor.authorMerino, Dolores
dc.contributor.authorTéllez Pérez, Francisco de Paula 
dc.contributor.authorMontes Ramírez, M. Luisa
dc.contributor.authorPulido, Federico
dc.contributor.authorRivero Juárez, Antonio
dc.contributor.authorRaffo, Miguel
dc.contributor.authorPérez Pérez, Montserrat
dc.contributor.authorMerchante, Nicolás
dc.contributor.authorCotarelo, Manuel
dc.contributor.authorPineda, Juan A.
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2025-07-10T07:25:54Z
dc.date.available2025-07-10T07:25:54Z
dc.date.issued2017
dc.identifier.issn1537-6591
dc.identifier.issn1058-4838
dc.identifier.urihttp://hdl.handle.net/10498/36672
dc.description.abstractBackground. Antiretroviral drugs with a lower potential to induce hepatic steatosis in human immunodeficiency virus (HIV) infection need to be identified. We compared the effect of switching efavirenz (EFV) to raltegravir (RAL) on hepatic steatosis among HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV plus 2 nucleoside analogues. Methods. HIV-infected patients on EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFLD were randomized 1:1 to switch from EFV to RAL (400 mg twice daily), maintaining nucleoside analogues unchanged, or to continue with EFV plus 2 nucleoside analogues. At baseline, eligible patients should show controlled attenuation parameter (CAP) values ≥238 dB/m. Changes in hepatic steatosis at 48 weeks of follow-up over baseline levels were measured by CAP. Results. Overall, 39 patients were included, and 19 of them were randomized to switch to RAL. At week 48, median CAP for the RAL group was 250 (Q1-Q3, 221-277) dB/m and 286 (Q1-Q3, 269-314) dB/m for the EFV group (P = .035). The median decrease in CAP values was -20 (Q1-Q3, -67 to 15) dB/m for the RAL arm and 30 (Q1-Q3, -17 to 49) dB/m for the EFV group (P = .011). CAP values <238 dB/m at week 48 were observed in 9 (47%) patients on RAL and 3 (15%) individuals on EFV (P = .029). Conclusions. After 48 weeks, HIV-infected individuals switching EFV to RAL showed decreases in the degree of hepatic steatosis, as measured by CAP, compared with those continuing with EFV. In addition, the proportion of patients without significant hepatic steatosis after 48 weeks was greater for those who switched to RAL. Clinical Trials Registration. NCT01900015.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceClinical Infectious Diseases - 2017, Vol. 65 n. 6 pp. 1012-1019es_ES
dc.subjectHIVes_ES
dc.subjectnonalcoholic fatty liver diseasees_ES
dc.subjectefavirenzes_ES
dc.subjectraltegravires_ES
dc.titleChanges in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1093/CID/CIX467
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional